UpcomingPDUFA target action date

BBP-418

BridgeBio Pharma (BBIO)

Marketer take

Potential first therapy in a very small neuromuscular population, where patient identification and specialist outreach drive launch.

Sponsor company
BridgeBio Pharma (BBIO)
Indication
Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)
Therapeutic area
Neurology, Rare disease
Event
PDUFA target action date
Date
Nov 27, 2026
Status
Upcoming
Source
company press release
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move